» Articles » PMID: 23548843

Statin Use and Calcific Uremic Arteriolopathy: a Matched Case-control Study

Overview
Journal Am J Nephrol
Publisher Karger
Specialty Nephrology
Date 2013 Apr 4
PMID 23548843
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Calcific uremic arteriolopathy (CUA), also known as calciphylaxis, is characterized by vascular calcification, thrombosis and intense inflammation. Prior research has shown that statins have anticalcification, antithrombotic and antiinflammatory properties; however, the association between statin use and CUA has not been investigated.

Methods: This matched case-control study included 62 adult maintenance hemodialysis (HD) patients with biopsy-confirmed CUA diagnosed between the years 2002 and 2011 (cases). All cases were hospitalized at the time of diagnosis. Controls (n = 124) were hospitalized maintenance HD patients without CUA (matched to cases by gender and timing of hospitalization). Univariate and multivariable logistic regression models were applied to compute odds ratio (OR) and 95% confidence intervals (CI) for CUA in statin users, and also to examine previously described associations.

Results: The mean age of cases was 58 years. Most were females (68%), and of white race (64%). Statin use was more common in controls than in cases (39 vs. 19%, p < 0.01). Statin use was associated with lower odds of CUA in unadjusted (OR 0.38, 95% CI 0.18-0.79) and adjusted (OR 0.20, 95% CI 0.05-0.88) analyses. Hypercalcemia (OR 2.25, 95% CI 1.14-4.43), hypoalbuminemia (OR 5.73, 95% CI 2.79-11.77), calcitriol use (OR 5.69, 95% CI 1.02-31.77) and warfarin use (OR 4.30, 95% CI 1.57-11.74) were positively associated with CUA in adjusted analyses whereas paricalcitol and doxercalciferol were not (OR 1.33, 95% CI 0.54-3.27).

Conclusion: Statin use may be negatively associated with odds of CUA. Further large prospective studies with attention to potential confounders are needed to confirm these findings.

Citing Articles

Direct oral anticoagulants for oral anticoagulants-naïve Asian patients with atrial fibrillation and end-stage renal disease undergoing dialysis.

Roh J, Kim Y, Kim D, Park S, Park K, Kim M Sci Rep. 2024; 14(1):14679.

PMID: 38918543 PMC: 11199492. DOI: 10.1038/s41598-024-65541-z.


Surgical treatment of nonuremic calciphylaxis: a case report and review of literature.

Tamagake M, Nagao M, Miura C, Imai Y Case Reports Plast Surg Hand Surg. 2024; 10(1):1-6.

PMID: 38229696 PMC: 10790797. DOI: 10.1080/23320885.2022.2145962.


Clinical characteristics and treatment modalities in uremic and non uremic calciphylaxis - a dermatological single-center experience.

Yousuf S, Busch D, Renner R, Schliep S, Erfurt-Berge C Ren Fail. 2024; 46(1):2297566.

PMID: 38178572 PMC: 10773653. DOI: 10.1080/0886022X.2023.2297566.


Non-uremic Calciphylaxis With Possible Initial Misdiagnosis as Erythema Multiforme/Toxic Epidermal Necrolysis Successfully Treated as Inpatient.

Al Yacoub R, Jamalifard F, Ladna M, Walker A Cureus. 2023; 15(8):e43618.

PMID: 37719563 PMC: 10504681. DOI: 10.7759/cureus.43618.


CREST Syndrome in Systemic Sclerosis Patients - Is Dystrophic Calcinosis a Key Element to a Positive Diagnosis?.

Bobeica C, Niculet E, Craescu M, Parapiru E, Musat C, Dinu C J Inflamm Res. 2022; 15:3387-3394.

PMID: 35706527 PMC: 9191197. DOI: 10.2147/JIR.S361667.


References
1.
Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

2.
Weenig R . Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol. 2008; 58(3):458-71. DOI: 10.1016/j.jaad.2007.12.006. View

3.
PAYNE R, Little A, Williams R, Milner J . Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J. 1973; 4(5893):643-6. PMC: 1587636. DOI: 10.1136/bmj.4.5893.643. View

4.
Krane V, Wanner C . Statins, inflammation and kidney disease. Nat Rev Nephrol. 2011; 7(7):385-97. DOI: 10.1038/nrneph.2011.62. View

5.
Galimberti R, Farias E, Hidalgo Parra I, Algranati L, Kowalczuk A, Imperiali N . Cutaneous necrosis by calcific uremic arteriolopathy. Int J Dermatol. 2005; 44(2):101-6. DOI: 10.1111/j.1365-4632.2005.02169.x. View